KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to -$36.3 million.

  • Supernus Pharmaceuticals' Change in Accured Expenses fell 50527.11% to -$36.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.9 million, marking a year-over-year decrease of 46993.35%. This contributed to the annual value of -$15.0 million for FY2024, which is 5862.15% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Change in Accured Expenses stood at -$36.3 million for Q3 2025, which was down 50527.11% from $8.3 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Change in Accured Expenses peaked at $57.4 million during Q2 2021, and registered a low of -$63.1 million during Q3 2021.
  • Over the past 5 years, Supernus Pharmaceuticals' median Change in Accured Expenses value was -$6.0 million (recorded in 2024), while the average stood at -$4.0 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 41451.76% in 2021, then tumbled by 1100223.05% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $33.9 million in 2021, then tumbled by 232.46% to -$44.9 million in 2022, then soared by 99.4% to -$269000.0 in 2023, then crashed by 11002.23% to -$29.9 million in 2024, then dropped by 21.5% to -$36.3 million in 2025.
  • Its last three reported values are -$36.3 million in Q3 2025, $8.3 million for Q2 2025, and $3.9 million during Q1 2025.